Canada: Pharma In Brief - Canada: Federal Court Upholds Validity Of Patent For Escitalopram (CIPRALEX®)

Case: Apotex Inc. v. H. Lundbeck A/S

Drug: Escitalopram ((+)-Citalopram) (CIPRALEX®)

Nature of case: Impeachment Action and Counterclaim for Infringement

Successful party: H. Lundbeck A/S

Date of decision: March 12, 2013


Apotex Inc. ("Apotex") brought an action for impeachment seeking a declaration that Lundbeck's Canadian Patent No. 1,339,452 (the "'452 Patent") is invalid. Lundbeck counterclaimed for a declaration of infringement. The '452 Patent claims the compound known as Escitalopram or (+)-Citalopram. It is branded in Canada as CIPRALEX®. It has proved useful in the treatment of clinical depression. The '452 Patent claims (+)-Citalopram itself, as well as methods to make it and non-toxic salts thereof.

The Court held that the '452 Patent is valid. The inventive concept was the two enantiomers of Citalopram, and methods to separate them from the racemate. The state of the art did not disclose how to achieve this result. The Court found that the steps taken by Lundbeck were not obvious to the person skilled in the art, and also required a degree of inventiveness.

Apotex admitted infringement 'but for' the validity of the '452 Patent. Lundbeck sought and was granted an accounting of Apotex's profits and a permanent injunction.

The Experts

This case turned on expert opinion evidence. There was much disagreement between the parties as to the weight to attach to the opinions of the various experts. The Court stated from the outset that not only were all the experts superbly qualified to offer expert opinion to the Court, but they were, each and every one, over qualified. The challenge they faced, and the challenge facing the Court, was whether they were able, in a sense, to reduce their expertise to that of the skilled person in 1988.

The '452 Patent

The '452 Patent relates to the enantiomers of Citalopram and their use in the treatment of depression in humans. It also relates to methods for obtaining those enantiomers. Claims 1 through 5 relate to (+)-Citalopram itself, including in salt form and composition, while claims 6 through 11 relate to an intermediate compound and methods of using that compound to make (+)-Citalopram.

History of the Proceedings

Apotex has wanted to market its generic version of (+)-Citalopram for some time. In April 2007, Apotex served a Notice of Allegation upon Lundbeck Canada Inc. alleging the '452 Patent was invalid on various grounds. One of those grounds, an invalid selection patent, was not pursued by Apotex at this trial. Lundbeck subsequently filed a Notice of Application seeking an order prohibiting the Minister of Health from issuing a Notice of Compliance to Apotex until the expiry of the '452 Patent. Justice Harrington, who also rendered this decision for the Court, allowed Lundbeck's application.

The Court stated that it has developed the practice, where possible and practicable, to assign the trial to the judge who heard the Prohibition Application. This, without more, does not give rise to a conflict of interest or to an apprehension of bias.



Apotex argued that the claims for (+)-Citalopram as a compound, namely claims 1 through 5, are invalid as they were anticipated by the prior disclosure of (+)-Citalopram as a component of the racemate. It was common general knowledge that Citalopram was a racemate containing equal amounts of (+)-Citalopram and (-)-Citalopram and that the enantiomers might have different therapeutic effects from the other, and from the racemate itself.

The Court held that there was no prior disclosure in that the working of the prior patents would inevitably result in a racemic mixture, not in separate enantiomers. Therefore, the prior patents did not teach how to resolve Citalopram and did not disclose the therapeutic effects of (+)-Citalopram.


The Court held that Lundbeck was motivated to resolve Citalopram given the common general knowledge that each of the enantiomers might have different therapeutic effects in the body. The Court held that while motivation would make it obvious to try to resolve Citalopram, the test is whether it is very plain or, more or less self-evident that what is being tested ought to work. Motivation does not control the analysis. It was a neutral factor in this case.

The experts cited a number of methods by which (+)-Citalopram could be separated from its racemate, but the evidence at trial was focused on two methods: chemical resolution and chiral HPLC. For the chemical resolution technique, the Court held that this route simply gave rise to too many permutations and combinations. For the chiral HPLC technique, the Court held that given the great many variables, it was not at all obvious to use an HPLC column and it was not at all obvious that it would work.

A mosaic of prior art was put before the trial judge in an effort to establish that (+)-Citalopram was obvious. The Court held that no chemist in 1988 would have had the motivation to search for all of this prior art and that even if they had read everything, they would still have had to connect the dots. A party claiming obviousness must not only be able to demonstrate that the prior art exists, but must also show how the person of ordinary skill in the art would have been led to combine the relevant components from the mosaic of prior art. In the Court's view, an assembly of literature which "might" have led to (+)-Citalopram involved a considerable degree of inventiveness.


Apotex alleged that the Pamoic Addition Salt of (+)-Citalopram is toxic and that since claims 1 through 5 all encompass this salt, the patent falls for inutility. Apotex led no evidence to show whether or not the Pamoic Salt is indeed toxic. While Lundbeck's evidence on this issue was "not perfect", the Court held that it was not unreasonable for a court to accept imperfect evidence from one side against no evidence at all from the other. The Court opined that just about everything is toxic if taken in excess. This allegation was dismissed.

Insufficient Disclosure

Apotex argued that the '452 Patent should be declared void as a result of a statement in the specification which states "results upon administration to human beings have been very gratifying". This statement was untrue, as the enantiomers had not been tested on human beings until after the patent application was filed. The Court found that this sentence was not a technical one and was not essential, so the patent survived this ground of attack. None of the experts were misled by the one-liner in the patent specification, given that no human testing was reported in the '452 Patent.

The Court further held that depending on the outcome of Pfizer's application to the Supreme Court for reconsideration of its decision in Viagra, it may well be that it is not even open to Apotex to argue this particular point, as the Court previously considered Apotex's argument in the Prohibition Application. Since patent construction is a matter of law, "it might well be" that Apotex is bound by the construction the Court gave to the '452 Patent, upheld by the Federal Court of Appeal, in the earlier proceeding.

Sound Prediction

The Court found that Lundbeck had a sound basis for predicting that (+)-Citalopram would be useful in the treatment of depression in humans. The racemate had already proven to be useful, and the same type of in vivo and in vitro tests to which Citalopram had been subjected were run on (+)-Citalopram, which showed even greater potency.

Apotex urged the Court to find that the '452 Patent promised that (+)-Citalopram had greater therapeutic effect than Citalopram. The Court rejected this argument, as there was no explicit statement either in the disclosure or in the claims. The Court held that the claim portion of the specification takes precedence over the disclosure portion in that the disclosure is read so as to understand what is meant by the claims "but not to enlarge or contract the scope of the claims as written and thus understood". The insertion of Citalopram in the testing results in the '452 Patent was done as a point of reference and cannot be taken as a promise.


Having found the '452 Patent and each and every one of its claims to be valid, the Court went on to consider the issue of infringement by both Apotex and Apotex Pharmachem. Both admitted that in the event the patent was found to be valid in all respects, they have infringed.

Rather than seeking compensatory damages, Lundbeck elected for an accounting of profits. The Court held that the election is ordinarily accepted unless there are circumstances which would warrant withholding it from the successful party. There were no such circumstances in this case. Apotex made use of Lundbeck's intellectual property rights and must turn over the profits they made. Lundbeck's claim for punitive damages was rejected.


The '452 Patent was held to be valid and infringed by Apotex. Lundbeck was awarded an accounting of Apotex's profits. The Court also issued a permanent injunction prohibiting Apotex from making, selling, distributing, advertising, exposing for sale, stockpiling or possessing for the purposes of the foregoing or importing into Canada (+)-Citalopram prior to the expiration of the '452 Patent on September 9, 2014.

Link to decision:

Norton Rose Group

Norton Rose Group is a leading international legal practice. We offer a full business law service to many of the world's pre-eminent financial institutions and corporations from offices in Europe, Asia, Australia, Canada, Africa, the Middle East, Latin America and Central Asia.

Knowing how our clients' businesses work and understanding what drives their industries is fundamental to us. Our lawyers share industry knowledge and sector expertise across borders, enabling us to support our clients anywhere in the world. We are strong in financial institutions; energy; infrastructure, mining and commodities; transport; technology and innovation; and pharmaceuticals and life sciences.

We have more than 2900 lawyers operating from 43 offices in Abu Dhabi, Almaty, Amsterdam, Athens, Bahrain, Bangkok, Beijing, Bogotá, Brisbane, Brussels, Calgary, Canberra, Cape Town, Caracas, Casablanca, Dubai, Durban, Frankfurt, Hamburg, Hong Kong, Johannesburg, London, Melbourne, Milan, Montréal, Moscow, Munich, Ottawa, Paris, Perth, Piraeus, Prague, Québec, Rome, Shanghai, Singapore, Sydney, Tokyo, Toronto and Warsaw; and from associate offices in Dar es Salaam, Ho Chi Minh City and Jakarta.

Norton Rose Group comprises Norton Rose LLP, Norton Rose Australia, Norton Rose Canada LLP, Norton Rose South Africa (incorporated as Deneys Reitz Inc), and their respective affiliates.

On January 1, 2012, Macleod Dixon joined Norton Rose Group adding strength and depth in Canada, Latin America and around the world. For more information please visit

Norton Rose will join forces with Fulbright & Jaworski L.L.P on June 1, 2013, creating Norton Rose Fulbright a global legal practice with significant depth of expertise across the USA, Europe, Asia, Australia, Canada, Africa, the Middle East, Latin America and Central Asia.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.